Table 2.
Patient Characteristics and Medication Use Characteristics
| Characteristic | N = 230 |
|---|---|
| Age, mean (range) | 42 (16-79) |
| Gender | |
| Male, n (%) | 27 (11.7) |
| Female, n (%) | 203 (88.3) |
| Race | |
| White | 198 (86.1) |
| African American | 27 (11.7) |
| Other | 5 (2.1) |
| MIDAS, median (IQR)† | 70 (37.5-113) |
| Grade I (0-5, little disability), n (%) | 1 (0.4) |
| Grade II (6-10, mild disability), n (%) | 4 (1.7) |
| Grade III (11-20, moderate disability), n (%) | 18 (7.8) |
| Grade IV-A (21-40, severe disability), n (%) | 36 (15.7) |
| Grade IV-B (41-270, very severe disability), n (%) | 154 (67.0) |
| Daily or near daily headaches, n (%) | 126 (54.8) |
| Daily or near daily headaches for >6 months, n (%) | 98 (42.6) |
| Duration of daily or near daily headache (months), median (IQR) | 36 (16-60) |
| History of prophylaxis | |
| Number of agents previously tried, median (IQR) | 3 (2-5) |
| History of topiramate, n (%) | 187 (81.3) |
| Medication overuse, n (%) | 84 (36.5) |
| Medication overuse by class | |
| Triptans (sumatriptan, Treximet, Relpax, etc), n (%) | 23 (11.3) |
| OTC analgesics and OTC combination products (acetaminophen, ibuprofen, etc), n (%) | 32 (15.8) |
| Barbiturates and barbiturate-containing combination products (butalbital, Fioricet, etc), n (%) | 17 (8.4) |
| Opioids and opioid-containing combination products (oxycodone, codeine, etc), n (%) | 31 (15.3) |
†Counts do not add to 230 due to missing data.
IQR = interquartile range; MIDAS = MIgraine Disability ASsessment scale; OTC = over the counter.